Consistent with this, Tang et al. treated patients with AIS with di-3-n-butylphthalide from the third to the 14th day after disease onset and observed increased serum levels of VEGF and basic fibroblast growth factor after treatment (Tang et al., 2017). The gene discussed is FGF2; the disease is androgen insensitivity syndrome.